Roche this week said that it has officially moved its Madison, Wisc.-based unit, which is part of the company's RNA therapeutics group, to a new facility located within the University of Wisconsin Research Park.
The unit, called Roche Madison, was created through Roche's $125 million cash acquisition of Mirus Bio (see RNAi News, 7/24/2008). The transaction, which was designed to bolster Roche's RNA drug-delivery capabilities, included Mirus' polymer-based dynamic polyconjugate siRNA- delivery technology.
According to Roche, the new Roche Madison site currently has 45 staffers. The company said it plans to make additional hires over the next six to twelve months.